Alaunos Therapeutics Inc., a Delaware-based company, has announced a significant new equity purchase agreement with Mast Hill Fund, L.P. Under the terms of the agreement, Mast Hill has committed to purchasing up to $25 million worth of Alaunos's common stock. This arrangement also includes a registration rights agreement, allowing for structured and potentially strategic sales of the company's stock. Notably, the company retains control over the timing and quantity of stock sales to Mast Hill, ensuring flexibility in response to market conditions and the company's funding needs. The agreement capitalizes on exemptions from registration requirements, as Mast Hill is deemed an accredited investor.